Loading
A year of cemiplimab after surgery and radiotherapy for high-risk cutaneous squamous cell carcinoma cut the risk of recurrence or death by more than two thirds, the first adjuvant therapy to work in this skin cancer.
Phase 3 placebo-controlled trial of 415 patients with cutaneous squamous cell carcinoma at high risk of recurrence after surgery and postoperative radiotherapy (nodal disease with extracapsular extension, in-transit metastases, perineural invasion or recurrent tumours) randomised to cemiplimab or placebo for up to 48 weeks.
Disease-free survival at 24 months was 87.1 versus 64.1 percent (hazard ratio 0.32), with reductions in both locoregional and distant recurrence; grade 3 or higher adverse events were 23.9 versus 14.2 percent.
Adjuvant cemiplimab is a new standard for high-risk cutaneous squamous cell carcinoma after surgery and radiotherapy, particularly in patients with extracapsular nodal extension.
Shares Advanced cutaneous squamous cell carcinoma, Cemiplimab, New England Journal of Medicine.
Shares Advanced cutaneous squamous cell carcinoma, Cemiplimab, New England Journal of Medicine.
Shares Advanced cutaneous squamous cell carcinoma, Cemiplimab.
Shares Advanced cutaneous squamous cell carcinoma, Cemiplimab.
Shares Advanced cutaneous squamous cell carcinoma, Cemiplimab.
Shares C-POST (cemiplimab after surgery and radiotherapy for high-risk skin squamous cell carcinoma), Advanced cutaneous squamous cell carcinoma, Cemiplimab.
Shares C-POST (cemiplimab after surgery and radiotherapy for high-risk skin squamous cell carcinoma), Advanced cutaneous squamous cell carcinoma.